You have 9 free searches left this month | for more free features.

CD20

Showing 1 - 25 of 9,973

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

B-cell Lymphoma Trial in Sanhe (CD19/CD20 Dual-CAR-T cells)

Completed
  • B-cell Lymphoma
  • CD19/CD20 Dual-CAR-T cells
  • Sanhe, Hebei, China
    Hebei Yanda Ludaopei Hospital
Mar 6, 2022

COVID-19 Infection in Patients Receiving Anti-CD20 Therapy

Active, not recruiting
  • COVID-19
  • +3 more
  • Convalescent Plasma
  • Rochester, Minnesota
    Mayo Clinic
Jul 15, 2022

B-cell Leukemia Trial in Sanhe (CD19/CD20 Dual-CAR-T cells)

Completed
  • B-cell Leukemia
  • CD19/CD20 Dual-CAR-T cells
  • Sanhe, Hebei, China
    Hebei Yanda Ludaopei Hospital
Mar 6, 2022

B-cell Non-Hodgkin's Lymphoma Trial in Beijing (CD19/CD20 Dual-CAR-T cells)

Suspended
  • B-cell Non-Hodgkin's Lymphoma
  • CD19/CD20 Dual-CAR-T cells
  • Beijing, Beijing, China
    Beijing Tsinghua Changgung Hospital
Jan 29, 2022

Relapase and Refractory B-cell Non-Hodgkin's Lymphoma, Decitabine-primed Tandem CD19/CD20 CAR T Cells Trial in Beijing

Recruiting
  • Relapase and Refractory B-cell Non-Hodgkin's Lymphoma
  • Decitabine-primed Tandem CD19/CD20 CAR T Cells
  • Decitabine-primed Tandem CAR19/20 engineered T cells
  • Beijing, Beijing, China
    Biotherapeutic Department of Chinese PLA General Hospital
Mar 24, 2022

CD20-positive B-cell Non-Hodgkin Lymphoma Trial in Beijing (Recombinant anti-CD20 mAb-MMAE coupling agent for injection

Recruiting
  • CD20-positive B-cell Non-Hodgkin Lymphoma
  • Recombinant anti-CD20 monoclonal antibody-MMAE coupling agent for injection (TRS005)
  • Beijing, Beijing, China
    Chinese Academy of Medical Sciences, Cancer Hospital
May 24, 2022

Resolved Hepatitis B, CD20 Positive B-cell Lymphoma Trial (Entecavir)

Not yet recruiting
  • Resolved Hepatitis B
  • CD20 Positive B-cell Lymphoma
  • (no location specified)
Jul 10, 2022

CD20-positive Non-Hodgkin Lymphoma Trial in Seoul (Rituximab + MG4101)

Active, not recruiting
  • CD20-positive Non-Hodgkin Lymphoma
  • Rituximab + MG4101
  • Seoul, Korea, Republic of
    Seoul National University Hospital
Feb 4, 2022

PTLD, CAEBV, HLH Trial in Beijing (low-dose CD20 mAb injection)

Enrolling by invitation
  • PTLD
  • +2 more
  • low-dose CD20 monoclonal antibody injection
  • Beijing, Beijing, China
    Beijing Friendship Hospital
Feb 24, 2022

Aplastic Anemia Trial in Suzhou (CD20 mAb, ATG)

Recruiting
  • Aplastic Anemia
  • CD20 monoclonal antibody
  • ATG
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Aug 21, 2022

CAR Trial in Hefei (CD19/CD20 CAR-T cell infusion)

Recruiting
  • CAR
  • CD19/CD20 CAR-T cell infusion
  • Hefei, Anhui, China
    Anhui Provincial Hospital
Mar 4, 2021

Non-Hodgkin's Lymphoma Trial in New York, Philadelphia, Houston (hA20-humanized anti-CD20 antibody)

Completed
  • Non-Hodgkin's Lymphoma
  • hA20-humanized anti-CD20 antibody
  • New York, New York
  • +2 more
Aug 12, 2021

Hematological Tumors Trial in Beijing (TQB2825 injection)

Recruiting
  • Hematological Tumors
  • TQB2825 injection
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Aug 4, 2022

Lymphoma, B-Cell, Lymphoma, Non-hodgkins, Chronic Lymphocytic Leukemia Trial run by the NCI (Anti-cluster of differentiation 19

Terminated
  • Lymphoma, B-Cell
  • +3 more
  • Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptors (CAR) and Anti-cluster of differentiation 20 (CD20)-CAR T cells
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 26, 2022

B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory Trial in Beijing, Tianjin (LCAR-AIO cells product)

Recruiting
  • B-cell Lymphoma Recurrent
  • B-cell Lymphoma Refractory
  • LCAR-AIO cells product
  • Beijing, Beijing, China
  • +1 more
Apr 1, 2022

Large B-cell Lymphoma Trial in Philadelphia (mosunetuzumab, glofitamab, obinutuzumab)

Recruiting
  • Large B-cell Lymphoma
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
Jul 21, 2022

Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, B-cell Lymphoma Refractory Trial in Cologne,

Active, not recruiting
  • Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
  • +3 more
  • MB-CART20.1
  • Cologne, Germany
  • +1 more
Sep 20, 2021

CD20 Positive B Cell Non-Hodgkin's Lymphoma Trial in Guangzhou, Tianjin (B001)

Completed
  • CD20 Positive B Cell Non-Hodgkin's Lymphoma
  • B001
  • Guangzhou, Guangdong, China
  • +1 more
Nov 11, 2021

Early Stage Follicular Lymphoma WHO Grade 1/2 or 3a Trial in Heidelberg (Standard, Experimental)

Recruiting
  • Early Stage Follicular Lymphoma WHO Grade 1/2 or 3a
  • Standard
  • Experimental
  • Heidelberg, Germany
    University Hospital Heidelberg
Jul 10, 2022

Acute Lymphocytic Leukemia Trial in Beijing, Tianjin (LCAR-AIO Cells)

Recruiting
  • Acute Lymphocytic Leukemia
  • LCAR-AIO Cells
  • Beijing, Beijing, China
  • +1 more
May 31, 2022

Cladribine Therapy After Anti CD20 Therapy

Active, not recruiting
  • Multiple Sclerosis
  • Cladribine Oral Tablet
  • +2 more
  • Lugano, Ticino, Switzerland
    Neurocenter of Southern Switzerland, Ospedale Regionale di Lugan
Mar 22, 2022

B Cell Non-Hodgkin's Lymphoma Trial in Duarte (CD19/CD20-directed CAR-T cells)

Recruiting
  • B Cell Non-Hodgkin's Lymphoma
  • CD19/CD20-directed CAR-T cells
  • Duarte, California
    City of Hope Medical Center
Aug 10, 2022

Therapy Related Leukemia Trial in Guangdong (Sequential Treatment With different CART)

Recruiting
  • Therapy Related Leukemia
  • Sequential Treatment With different CART
  • Guangdong, Guangdong, China
    Southern Medical University Zhujiang Hospital
Aug 9, 2021

Membranous Nephropathy Trial in Bergamo, Ranica (MOR202)

Recruiting
  • Membranous Nephropathy
  • Bergamo, BG, Italy
  • +1 more
Mar 4, 2022

CD20 Positive Non Hodgkin Lymphoma Trial in United States (CPO107)

Recruiting
  • CD20 Positive Non Hodgkin Lymphoma
  • Los Angeles, California
  • +4 more
Aug 9, 2022